Finally, given the novelty of our findings no evaluation of ferroportin expression or otherwise has to our knowledge as yet been undertaken in subjects with or samples from patients with PAH nor indeed has any evaluation of CD163. This evidence concerns the gene CD163 and pulmonary arterial hypertension.